Sean Whooley is an Assistant Editor at MassDevice. With a strong focus on medicine and healthcare, he covers topics related to healthcare technology, medical innovations, and the intersection of business and wellness. His work has been featured in notable publications such as NewsBreak, The Robot Report, and Pharmaceutical Processing World.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Sean Whooley's articles predominantly focus on healthcare and pharmaceuticals, with a specific emphasis on medical technology, FDA approvals, medical devices, and the pharmaceutical industry. His coverage heavily features press releases and private sector announcements.
To effectively reach out to Sean, consider providing access to exclusive interviews or insights from key figures within the healthcare and pharmaceutical sectors. Additionally, offering in-depth analysis of new technologies or regulatory developments in the medical field could be particularly appealing to him. Given his interest in scientific themes as well, pitches related to cutting-edge research or technological advancements may also capture his attention.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Sean Whooley
The FDA said today that J&J's Abiomed unit issued a warning recommending the removal of certain Impella CP sets with SmartAssist.
By: Sean Whooley
ViCentra announced today that it began commercial-scale production of its Kaleido insulin pump technology at Phillips Medisize.
By: Sean Whooley
Since ViCentra closed an $85 million funding round in September 2025, the milestones have continued to stack up.
By: Sean Whooley
Procept BioRobotics (Nasdaq:PRCT) announced that it received FDA investigational device exemption (IDE) for a second Aquablation evaluation.
Getinge announced today that a court delivered a verdict in favor of Johnson & Johnson’s Abiomed in a patent spat with its Maquet subsidiary.
Intuitive (Nasdaq:ISRG) announced that it named Taylor Patton as its new chief commercial and marketing officer.
By: Sean Whooley
John Slump, co-founder and former president and CEO of Atraverse Medical, has now launched advisory fi Metis MedTech.
By: Sean Whooley
Medtrum said that a study of its automated insulin delivery technology demonstrated increased time in range for people with diabetes.
By: Sean Whooley
MannKind (Nasdaq:MNKD) announced today that it received FDA approval for its Afrezza inhaled insulin powder for children.
The U.S. Court of Appeals for the Federal Circuit in Washington, D.C., has sided with EOFlow in its patent spat with Insulet (Nasdaq:PODD).
